Technische Daten
Change(s) made:Complete revision
Status:Research Use Only (RUO)
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human PODXL
Vorbehandlung:ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic, membranous
Kontrolle:Kidney, breast cancer
Synonyme:Podocalyxin, PCLP, PCLP1, podocalyxin-like isoform 1 precursor, Podocalyxin like protein.
Verfügbar in folgenden Ländern:worldwide

PODXL is a highly glycosylated type I transmembrane protein associated with CD34. Its expression has been reported in the cytoplasm of some tumor cells, in some cases protruding toward the cell membrane, but not in the nucleus. PODXL is highly expressed by glomerular podocytes, vascular endothelium, hematopoietic cells and breast epithelial cells. The clinical significance of PODXL in the progression of various cancers has been studied, and it was found as a stem cell marker in the testicular cancer. The later findings proved that, PODXL associates with advanced tumor phenotype in some cancers, including breast cancer, colorectal cancer, esophageal cancer, gastric cancer, glioblastoma multiforme, lung adenocarcinoma, oral squamous cell carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urothelial bladder cancer.